 This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data collection starts inclusion visit, and is designed to evaluate demographic and clinical predictors of persistence with this treatment. 